The race to develop the world's best CAR-T therapy for cancer has inspired some fancy marketing efforts on behalf of some of the leaders in the field. Case in point: France's Cellectis ($CLLS), which is developing an R&D hub in Manhattan, has unveiled a cool new 2-minute video which illustrates how it plans to use TALEN gene editing tech to create allogeneic, or off-the-shelf, engineered T cell treatments. Keep in mind, though, that while Cellectis' approach has helped inspire a big IPO for the company, the company is also quick to acknowledge that it's only been tried in animals so far. The first human study lies ahead.